Urine-derived podocytes from steroid resistant nephrotic syndrome patients as a model for renal-progenitor derived extracellular vesicles effect and drug screening.
Alport syndrome
Disease models
Exosomes
Permeability
Personalized therapy
Renal progenitor cells
SENP2
SUMO1
SUMOylation
Steroid-resistant nephrotic syndrome
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
received:
14
02
2024
accepted:
04
08
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
14
8
2024
Statut:
epublish
Résumé
Personalized disease models are crucial for evaluating how diseased cells respond to treatments, especially in case of innovative biological therapeutics. Extracellular vesicles (EVs), nanosized vesicles released by cells for intercellular communication, have gained therapeutic interest due to their ability to reprogram target cells. We here utilized urinary podocytes obtained from children affected by steroid-resistant nephrotic syndrome with characterized genetic mutations as a model to test the therapeutic potential of EVs derived from kidney progenitor cells (nKPCs). EVs were isolated from nKPCs derived from the urine of a preterm neonate. Three lines of urinary podocytes obtained from nephrotic patients' urine and a line of Alport syndrome patient podocytes were characterized and used to assess albumin permeability in response to nKPC-EVs or various drugs. RNA sequencing was conducted to identify commonly modulated pathways after nKPC-EV treatment. siRNA transfection was used to demonstrate the involvement of SUMO1 and SENP2 in the modulation of permeability. Treatment with the nKPC-EVs significantly reduced permeability across all the steroid-resistant patients-derived and Alport syndrome-derived podocytes. At variance, podocytes appeared unresponsive to standard pharmacological treatments, with the exception of one line, in alignment with the patient's clinical response at 48 months. By RNA sequencing, only two genes were commonly upregulated in nKPC-EV-treated genetically altered podocytes: small ubiquitin-related modifier 1 (SUMO1) and Sentrin-specific protease 2 (SENP2). SUMO1 and SENP2 downregulation increased podocyte permeability confirming the role of the SUMOylation pathway. nKPCs emerge as a promising non-invasive source of EVs with potential therapeutic effects on podocytes with genetic dysfunction, through modulation of SUMOylation, an important pathway for the stability of podocyte slit diaphragm proteins. Our findings also suggest the feasibility of developing a non-invasive in vitro model for screening regenerative compounds on patient-derived podocytes.
Sections du résumé
BACKGROUND
BACKGROUND
Personalized disease models are crucial for evaluating how diseased cells respond to treatments, especially in case of innovative biological therapeutics. Extracellular vesicles (EVs), nanosized vesicles released by cells for intercellular communication, have gained therapeutic interest due to their ability to reprogram target cells. We here utilized urinary podocytes obtained from children affected by steroid-resistant nephrotic syndrome with characterized genetic mutations as a model to test the therapeutic potential of EVs derived from kidney progenitor cells (nKPCs).
METHODS
METHODS
EVs were isolated from nKPCs derived from the urine of a preterm neonate. Three lines of urinary podocytes obtained from nephrotic patients' urine and a line of Alport syndrome patient podocytes were characterized and used to assess albumin permeability in response to nKPC-EVs or various drugs. RNA sequencing was conducted to identify commonly modulated pathways after nKPC-EV treatment. siRNA transfection was used to demonstrate the involvement of SUMO1 and SENP2 in the modulation of permeability.
RESULTS
RESULTS
Treatment with the nKPC-EVs significantly reduced permeability across all the steroid-resistant patients-derived and Alport syndrome-derived podocytes. At variance, podocytes appeared unresponsive to standard pharmacological treatments, with the exception of one line, in alignment with the patient's clinical response at 48 months. By RNA sequencing, only two genes were commonly upregulated in nKPC-EV-treated genetically altered podocytes: small ubiquitin-related modifier 1 (SUMO1) and Sentrin-specific protease 2 (SENP2). SUMO1 and SENP2 downregulation increased podocyte permeability confirming the role of the SUMOylation pathway.
CONCLUSIONS
CONCLUSIONS
nKPCs emerge as a promising non-invasive source of EVs with potential therapeutic effects on podocytes with genetic dysfunction, through modulation of SUMOylation, an important pathway for the stability of podocyte slit diaphragm proteins. Our findings also suggest the feasibility of developing a non-invasive in vitro model for screening regenerative compounds on patient-derived podocytes.
Identifiants
pubmed: 39143486
doi: 10.1186/s12967-024-05575-z
pii: 10.1186/s12967-024-05575-z
doi:
Substances chimiques
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
762Subventions
Organisme : NIDDK NIH HHS
ID : 1R01DK123234
Pays : United States
Organisme : NIDDK NIH HHS
ID : 1R01DK123234
Pays : United States
Organisme : H2020 European Research Council
ID : Consolidator grant 101045467
Informations de copyright
© 2024. The Author(s).
Références
Fukasawa H, Bornheimer S, Kudlicka K, Farquhar MG. Slit diaphragms contain tight junction proteins. J Am Soc Nephrol. 2009;20(7):1491–503.
pubmed: 19478094
pmcid: 2709684
doi: 10.1681/ASN.2008101117
Bierzynska A, Saleem M. Recent advances in understanding and treating nephrotic syndrome. F1000Res. 2017;6:121.
pubmed: 28232870
pmcid: 5302149
doi: 10.12688/f1000research.10165.1
Kanasaki K, Kanda Y, Palmsten K, Tanjore H, Lee SB, Lebleu VS, et al. Integrin beta1-mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus. Dev Biol. 2008;313(2):584–93.
pubmed: 18082680
doi: 10.1016/j.ydbio.2007.10.047
Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61–74.
pubmed: 29910038
doi: 10.1016/S0140-6736(18)30536-1
Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880–90.
pubmed: 30342869
doi: 10.1016/S2352-4642(18)30283-9
Nagata M. Podocyte injury and its consequences. Kidney Int. 2016;89(6):1221–30.
pubmed: 27165817
doi: 10.1016/j.kint.2016.01.012
Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279–89.
pubmed: 25349199
doi: 10.1681/ASN.2014050489
Williams AE, Esezobor CI, Lane BM, Gbadegesin RA. Hiding in plain sight: genetics of childhood steroid-resistant nephrotic syndrome in Sub-saharan Africa. Pediatr Nephrol. 2023;38(7):2003–12.
pubmed: 36459247
doi: 10.1007/s00467-022-05831-8
Hejazian SM, Zununi Vahed S, Moghaddas Sani H, Nariman-Saleh-Fam Z, Bastami M, et al. Steroid-resistant nephrotic syndrome: pharmacogenetics and epigenetic points and views. Expert Rev Clin Pharmacol. 2020;13(2):147–56.
pubmed: 31847609
doi: 10.1080/17512433.2020.1702877
Kanwar YS, Rosenzweig LJ. Altered glomerular permeability as a result of focal detachment of the visceral epithelium. Kidney Int. 1982;21(4):565–74.
pubmed: 7098274
doi: 10.1038/ki.1982.63
Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Ren Physiol. 2003;285(1):F40–48.
doi: 10.1152/ajprenal.00404.2002
Oliveira Arcolino F, Tort Piella A, Papadimitriou E, Bussolati B, Antonie DJ, Murray P, et al. Human urine as a noninvasive source of kidney cells. Stem Cells Int. 2015;2015:362562.
pubmed: 26089913
pmcid: 4451513
doi: 10.1155/2015/362562
Iampietro C, Bellucci L, Arcolino FO, Arigoni M, Alessandri L, Gomez Y, et al. Molecular and functional characterization of urine-derived podocytes from patients with Alport syndrome. J Pathol. 2020;252(1):88–100.
pubmed: 32652570
doi: 10.1002/path.5496
Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other Extracellular vesicles as new remedies in the Therapy of Inflammatory diseases. Cells. 2019;8(12):E1605.
doi: 10.3390/cells8121605
Biancone L, Bruno S, Deregibus MC, Tetta C, Camussi G. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transpl. 2012;27(8):3037–42.
doi: 10.1093/ndt/gfs168
Bianchi F, Sala E, Donadei C, Capelli I, La Manna G. Potential advantages of acute kidney injury management by mesenchymal stem cells. World J Stem Cells. 2014;6(5):644–50.
pubmed: 25426262
pmcid: 4178265
doi: 10.4252/wjsc.v6.i5.644
Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78(9):838–48.
pubmed: 20703216
doi: 10.1038/ki.2010.278
Ju Gqun, Cheng J, Zhong L, Wu S, Zou X, yu, Zhang G et al. yuan,. Microvesicles derived from human umbilical cord mesenchymal stem cells facilitate tubular epithelial cell dedifferentiation and growth via hepatocyte growth factor induction. PLoS One. 2015;10(3):e0121534.
Bellucci L, Montini G, Collino F, Bussolati B. Mesenchymal stromal cell-derived extracellular vesicles pass through the Filtration Barrier and protect podocytes in a 3D glomerular model under continuous perfusion. Tissue Eng Regen Med. 2021;18(4):549–60.
pubmed: 34313970
pmcid: 8325748
doi: 10.1007/s13770-021-00374-9
Medica D, Franzin R, Stasi A, Castellano G, Migliori M, Panichi V, et al. Extracellular vesicles derived from endothelial progenitor cells protect human glomerular endothelial cells and podocytes from complement- and cytokine-mediated Injury. Cells. 2021;10(7):1675.
pubmed: 34359843
pmcid: 8304261
doi: 10.3390/cells10071675
Arcolino FO, Zia S, Held K, Papadimitriou E, Theunis K, Bussolati B, et al. Urine of Preterm neonates as a Novel source of kidney progenitor cells. J Am Soc Nephrol. 2016;27(9):2762–70.
pubmed: 26940093
pmcid: 5004650
doi: 10.1681/ASN.2015060664
Arcolino FO, Hosgood S, Akalay S, Jordan N, Herman J, Elliott T, et al. De novo SIX2 activation in human kidneys treated with neonatal kidney stem/progenitor cells. Am J Transpl. 2022;22(12):2791–803.
doi: 10.1111/ajt.17164
Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529–61.
pubmed: 32382828
pmcid: 7316686
doi: 10.1007/s00467-020-04519-1
Furuta I, Zhai T, Umazume T, Ishikawa S, Nakagawa K, Akaishi R, et al. Increased podocyturia in pregnant women compared to non-pregnant women. J Obstet Gynaecol Res. 2017;43(5):873–9.
pubmed: 28188955
doi: 10.1111/jog.13283
Saleem MA, O’Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002;13(3):630–8.
pubmed: 11856766
doi: 10.1681/ASN.V133630
Ivanova EA, Arcolino FO, Elmonem MA, Rastaldi MP, Giardino L, Cornelissen EM, van den Heuvel LP, Levtchenko EN. Cystinosin deficiency causes podocyte damage and loss associated with increased cell motility. Kidney Int. 2016;89(5):1037–48.
pubmed: 27083281
doi: 10.1016/j.kint.2016.01.013
Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A. 1998;95(25):14723–8.
pubmed: 9843956
pmcid: 24516
doi: 10.1073/pnas.95.25.14723
Buono L, Scalabrin S, De Iuliis M, Tanzi A, Grange C, Tapparo M, Nuzzi R, Bussolati B. Mesenchymal stem cell-derived extracellular vesicles protect human corneal endothelial cells from endoplasmic reticulum stress-mediated apoptosis. Int J Mol Sci. 2021;22(9):4930.
pubmed: 34066474
pmcid: 8125791
doi: 10.3390/ijms22094930
Brossa A, Grange C, Mancuso L, Annaratone L, Satolli MA, Mazzone M, et al. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Oncotarget. 2015;6(13):11295–309.
pubmed: 25948774
pmcid: 4484457
doi: 10.18632/oncotarget.3123
Cavallari C, Figliolini F, Tapparo M, Cedrino M, Trevisan A, Positello L, et al. miR-130a and Tgfβ content in Extracellular vesicles derived from the serum of subjects at High Cardiovascular Risk predicts their In-Vivo angiogenic potential. Sci Rep. 2020;10(1):706.
pubmed: 31959759
pmcid: 6971269
doi: 10.1038/s41598-019-55783-7
Rampino T, Gregorini M, Guidetti C, Broggini M, Marchini S, Bonomi R, et al. KCNA1 and TRPC6 ion channels and NHE1 exchanger operate the biological outcome of HGF/scatter factor in renal tubular cells. Growth Factors. 2007;25(6):382–91.
pubmed: 18365869
doi: 10.1080/08977190801892184
Verta R, Grange C, Skovronova R, Tanzi A, Peruzzi L, Deregibus MC, et al. Generation of spike-extracellular vesicles (S-EVs) as a Tool to mimic SARS-CoV-2 Interaction with host cells. Cells. 2022;11(1):146.
pubmed: 35011708
pmcid: 8750506
doi: 10.3390/cells11010146
Skovronova R, Grange C, Dimuccio V, Deregibus MC, Camussi G, Bussolati B. Surface marker expression in small and Medium/Large mesenchymal stromal cell-derived extracellular vesicles in naive or apoptotic Condition using Orthogonal techniques. Cells. 2021;10(11):2948.
pubmed: 34831170
pmcid: 8616318
doi: 10.3390/cells10112948
Lu Y, Ye Y, Bao W, Yang Q, Wang J, Liu Z, et al. Genome-wide identification of genes essential for podocyte cytoskeletons based on single-cell RNA sequencing. Kidney Int. 2017;92(5):1119–29.
pubmed: 28709640
doi: 10.1016/j.kint.2017.04.022
Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 2005;166(2):545–55.
pubmed: 15681837
pmcid: 1602314
doi: 10.1016/S0002-9440(10)62276-6
Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–8.
pubmed: 18724379
pmcid: 4109287
doi: 10.1038/nm.1857
Coppo R, Camilla R, Porcellini MG, Peruzzi L, Gianoglio B, Amore A, et al. Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study. Nephrol Dial Transpl. 2012;27(5):1902–10.
doi: 10.1093/ndt/gfs035
Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int. 2005;68(6):2473–83.
pubmed: 16316324
doi: 10.1111/j.1523-1755.2005.00723.x
Maruyama T, Abe Y, Niikura T. SENP1 and SENP2 regulate SUMOylation of amyloid precursor protein. Heliyon. 2018;4(4):e00601.
pubmed: 29862363
pmcid: 5968171
doi: 10.1016/j.heliyon.2018.e00601
Hang J, Dasso M. Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem. 2002;277(22):19961–6.
pubmed: 11896061
doi: 10.1074/jbc.M201799200
Haynes JM, Selby JN, Vandekolk TH, Abad IPL, Ho JK, Lieuw WL, et al. Induced Pluripotent Stem Cell-Derived Podocyte-Like cells as models for assessing mechanisms underlying heritable Disease phenotype: initial studies using two Alport Syndrome patient lines indicate impaired Potassium Channel activity. J Pharmacol Exp Ther. 2018;367(2):335–47.
pubmed: 30104322
doi: 10.1124/jpet.118.250142
Musah S, Dimitrakakis N, Camacho DM, Church GM, Ingber DE. Directed differentiation of human induced pluripotent stem cells into mature kidney podocytes and establishment of a Glomerulus Chip. Nat Protoc. 2018;13(7):1662–85.
pubmed: 29995874
pmcid: 6701189
doi: 10.1038/s41596-018-0007-8
Lazzeri E, Ronconi E, Angelotti ML, Peired A, Mazzinghi B, Becherucci F, et al. Human urine-derived renal progenitors for Personalized modeling of genetic kidney disorders. J Am Soc Nephrol. 2015;26(8):1961.
pubmed: 25568173
pmcid: 4520157
doi: 10.1681/ASN.2014010057
Grange C, Tritta S, Tapparo M, Cedrino M, Tetta C, Camussi G, et al. Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci Rep. 2019;9(1):4468.
pubmed: 30872726
pmcid: 6418239
doi: 10.1038/s41598-019-41100-9
Jiang Zzhen, Liu Y, mei, Niu X, Yin J yong, Hu B, Guo S, chun et al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Res Ther. 2016;7:24.
Sedrakyan S, Villani V, Da Sacco S, Tripuraneni N, Porta S, Achena A, et al. Amniotic fluid stem cell-derived vesicles protect from VEGF-induced endothelial damage. Sci Rep. 2017;7(1):16875.
pubmed: 29203902
pmcid: 5715019
doi: 10.1038/s41598-017-17061-2
Duan Y, Luo Q, Wang Y, Ma Y, Chen F, Zhu X, et al. Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLR4 and protect against diabetic nephropathy. J Biol Chem. 2020;295(37):12868–84.
pubmed: 32580945
pmcid: 7489897
doi: 10.1074/jbc.RA120.012522
Zhao T, Jin Q, Kong L, Zhang D, Teng Y, Lin L, et al. microRNA-15b-5p shuttled by mesenchymal stem cell-derived extracellular vesicles protects podocytes from diabetic nephropathy via downregulation of VEGF/PDK4 axis. J Bioenerg Biomembr. 2022;54(1):17–30.
pubmed: 34806156
doi: 10.1007/s10863-021-09919-y
Tossidou I, Himmelseher E, Teng B, Haller H, Schiffer M. SUMOylation determines turnover and localization of nephrin at the plasma membrane. Kidney Int. 2014;86(6):1161–73.
pubmed: 24940800
doi: 10.1038/ki.2014.198
Wu Q, Aroankins TS, Cheng L, Fenton RA. SUMOylation Landscape of renal cortical Collecting Duct cells. J Proteome Res. 2019;18(10):3640–8.
pubmed: 31502464
doi: 10.1021/acs.jproteome.9b00306